XML 38 R19.htm IDEA: XBRL DOCUMENT v3.19.3
General (Details) - USD ($)
$ in Thousands
 1 Months Ended
Feb. 28, 2019
Jan. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Dec. 31, 2017
General (Textual)                
Royalty payments   $ 180            
Accumulated deficit     $ (32,759)   $ (29,997)      
Stockholders' equity     (147) $ 465 $ 212 $ (2,196) $ (2,267) $ (3,098)
Principal amount     $ 1,353          
Description of royalties payable Pursuant to the License Agreement (as amended), the royalties payable by Wize Israel to Resdevco shall be $150,000 per year through 2021. A one-time payment to Resdevco by Wize Israel in an amount of $650,000 shall be due no later than the second anniversary of the receipt of FDA approval (the "Deferred Amount"); however, following FDA approval, if annual royalties due to Resdevco by Wize Israel exceed the Minimum Royalties (as defined in the License Agreement), an amount equal to 50% of such excess shall be added towards settlement of the Deferred Amount. As to royalty payments, Resdevco shall be entitled to the greater of $.60, or a percentage of revenues, not to exceed 10%, from sales made in the United States and other countries, excluding Israel, China and Ukraine, but not less than the the Minimum Royalties.